William Martens Lee

William Martens Lee

Auto-generated profile, based on publicly available information

William Martens Lee

Division of Gastroenterology and Hepatology University of Texas Southwestern Dallas Texas USA

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2003 in New England Journal of Medicine
Verified
Journal Article
Closed access
WLWilliam M. Lee
William M. Lee
Drug-induced hepatic injury accounts for more than 50 percent of cases of acute liver failure in the United States. More than 75 percent of idiosyncratic drug reactions result in liver transplantation or death. This review discusses the pathogenesis of drug-induced liver injury, common adverse drug reactions involving the liver, and the drug-approval process. Monitoring for and recognition of drug-induced hepatotoxicity may prevent some cases of acute hepatic failure.

19 April 2005 in Hepatology
Verified
Journal Article
Open access
PDF file
JPJulie Polson
Julie Polson
WLWilliam M. Lee
William M. Lee

1 September 2019 in The Lancet
Verified
Journal Article
Closed access
RSR Todd Stravitz
R Todd Stravitz
WLWilliam M Lee
William M Lee

19 December 2007 in Hepatology
Verified
Journal Article
Open access
PDF file
WLWilliam M. Lee
William M. Lee
RSRobert H. Squires
Robert H. Squires
SNScott L. Nyberg
Scott L. Nyberg
EDEdward Doo
Edward Doo
JHJay H. Hoofnagle
Jay H. Hoofnagle
Acute liver failure (ALF) is a rare but challenging clinical syndrome with multiple causes; a specific etiology cannot be identified in 15% of adult and 50% of pediatric cases. The course of ALF is variable and the mortality rate is high. Liver transplantation is the only therapy of proven benefit, but the rapidity of progression and the variable course of ALF limit its use. Currently in the United States, spontaneous survival occurs in approximately 45%, liver transplantation in 25%, and death without transplantation in 30% of adults with ALF. Higher rates of spontaneous recovery (56%) and transplantation (31%) with lower rates of death (13%) occur in children. The outcome of ALF varies by etiology, favorable prognoses being found with acetaminophen overdose, hepatitis A, and ischemia (≈60% spontaneous survival), and poor prognoses with drug‐induced ALF, hepatitis B, and indeterminate cases (≈25% spontaneous survival). Excellent intensive care is critical in management of patients with ALF. Nonspecific therapies are of unproven benefit. Future possible therapeutic approaches include N‐acetylcysteine, hypothermia, liver assist devices, and hepatocyte transplantation. Advances in stem cell research may allow provision of cells for bioartificial liver support. ALF presents many challenging opportunities in both clinical and basic research. (HEPATOLOGY 2008.)

1 September 2009 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
WLWilliam M. Lee
William M. Lee
LHLinda S. Hynan
Linda S. Hynan
LRLorenzo Rossaro
Lorenzo Rossaro
RFRobert J. Fontana
Robert J. Fontana
RSR. Todd Stravitz
R. Todd Stravitz
PRPatricia R. Robuck
Patricia R. Robuck

1 February 2010 in Gastroenterology
Verified
Journal Article
Open access
PDF file
ALAnna S. Lok
Anna S. Lok
RSRichard K. Sterling
Richard K. Sterling
JEJames E. Everhart
James E. Everhart
EWElizabeth C. Wright
Elizabeth C. Wright
JHJohn C. Hoefs
John C. Hoefs
JDJules L. Dienstag
Jules L. Dienstag
Background & Aims The outcome of patients with hepatocellular carcinoma (HCC) remains poor because of late diagnosis. The aim of this study was to compare the accuracy of α-fetoprotein (AFP) and des-γ-carboxy prothrombin (DCP) in the early diagnosis of HCC. Methods Among 1031 patients randomized in the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis (HALT-C) Trial, a nested case-control study of 39 HCC cases (24 early stage) and 77 matched controls was conducted to compare the performance of AFP and DCP. Testing was performed on sera from 12 months prior (month −12) to the time of HCC diagnosis (month 0). Results The sensitivity and specificity of DCP at month 0 was 74% and 86%, respectively, at a cutoff of 40 mAU/mL and 43% and 100%, respectively, at a cutoff of 150 mAU/mL. The sensitivity and specificity of AFP at month 0 was 61% and 81% at a cutoff of 20 ng/mL and 22% and 100% at a cutoff of 200 ng/mL. At month −12, the sensitivity and specificity at the low cutoff was 43% and 94%, respectively, for DCP and 47% and 75%, respectively, for AFP. Combining both markers increased the sensitivity to 91% at month 0 and 73% at month 12, but the specificity decreased to 74% and 71%, respectively. Diagnosis of early HCC was triggered by surveillance ultrasound in 14, doubling of AFP in 5, and combination of tests in 5 patients. Conclusions Biomarkers are needed to complement ultrasound in the detection of early HCC, but neither DCP nor AFP is optimal.